Clinical trials: Soft Tissue Sarcomas
Advanced Solid Tumors, Metastatic Pancreatic Cancer
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help.
- Conditions
- Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer
- Trial name
- NCT04222413
- Testing
- Metarrestin
- Where
- 2 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Soft Tissue Sarcoma
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.
- Trial name
- NCT05679921
- Testing
- pembrolizumab, pazopanib
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- Yonsei University
Sarcoma
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR-α and -β; and the receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell carcinoma (RCC) and advanced STS.
- Trial name
- NCT03798106
- Testing
- Durvalumab, pazopanib
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Yonsei University
Sarcoma, Soft Tissue
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
The purpose of this study is to assess how the body handles olaratumab when it is given with another drug called doxorubicin. The safety and tolerability of these drugs will be studied.
- Trial name
- NCT02326025
- Testing
- Olaratumab, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
Phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable, locally advanced or metastatic solid tumors.
- Conditions
- Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Cancer
- Trial name
- EMPIRE (NCT06084689)
- Testing
- Ezabenlimab + BI907828
- Where
- 6 sites in France
- Sponsor
- Institut Bergonié
Sarcoma,Soft Tissue, Brachytherapy
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
To evaluate the effectiveness and safety of radioactive particles in combination with the PARP inhibitor fluzoparib in the treatment of advanced inoperable soft tissue sarcoma.
- Conditions
- Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors
- Trial name
- RAFAS-001 (NCT05894018)
- Testing
- Fluzoparib, Radioactive particle implantation
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fujun Zhang
Sarcoma
Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients with recurrent or…
- Trial name
- NCT00003316
- Testing
- gemcitabine hydrochloride
- Where
- 40 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Advanced Malignancies
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose.
- Trial name
- NCT03474640
- Testing
- Part A, Part B
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- TopAlliance Biosciences
Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma
- Trial name
- NCT00069940
- Testing
- sargramostim, telomerase: 540-548 peptide vaccine
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan hydrochloride in treating younger patients with solid tumors that have come back (relapsed) or that have not responded to standard therapy…
- Conditions
- Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Trial name
- NCT02095132
- Testing
- Adavosertib, Irinotecan Hydrochloride
- Where
- 24 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
A Study Involving Collection of Samples and Data From Sarcoma Patients Receiving Immunotherapy
The researchers are doing this study to improve their knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma by collecting information from participants' medical records who have been…
- Trial name
- NCT06113315
- Where
- 7 sites in United States
- Volunteers
- 250 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Neuroblastoma, Soft Tissue Cancer
A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma
The purpose of this study is to evaluate safety and efficacy of naxitamab, granulocyte macrophage Colony Stimulating Factor (GM CSF) and Isofosfamide/Carboplatin/Etoposide (NICE) for Patients With Relapsed /Refractory, soft…
- Trial name
- NICE (NCT06438614)
- Testing
- HITS, Naxitamab + GM-CSF cycles, NICE
- Where
- Spain
- Volunteers
- 47 people
- Sponsor
- Fundació Sant Joan de Déu
Leiomyosarcoma, Liposarcoma
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery…
- Conditions
- Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3
- Trial name
- NCT02923778
- Testing
- Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging
- Where
- 17 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Soft Tissue
Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)
Investigators will determine whether MRSI using hyperpolarized [1-13C]pyruvate provide useful information of tumor malignancy in MRI-indeterminate cases.
- Trial name
- HPMSS (NCT03759704)
- Testing
- Hyperpolarized 13CPyruvate
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Advanced or Metastatic Liposarcoma or Leiomyosarcoma
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
The purpose of this study is to find the optimal dose of trabectedin for Chinese patients with locally advanced or metastatic L-sarcoma (liposarcoma or leiomyosarcoma) who were previously treated (in any order) with at least an…
- Trial name
- NCT01692678
- Testing
- Trabectedin, Dacarbazine
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Soft Tissue Sarcoma
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.
- Trial name
- FLASH (NCT04733183)
- Testing
- Dacarbazine, onfekafusp alfa
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Philogen S.p.A.
Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors
This is a transnational prospective randomized trial comparing definitive carbon ion therapy versus photon or combined photon and protontherapy as standard treatment for unresectable or macroscopically uncompleted resected…
- Trial name
- ETOILE (NCT02838602)
- Testing
- Carbon ions therapy, Advanced external radiotherapy by Xrays or protons
- Where
- 21 sites in France
- Volunteers
- 250 people
- Sponsor
- Hospices Civils de Lyon
Cervical Cancer, Endometrial Cancer
Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer
RATIONALE: Giving pain medication into the space between the wall of the spinal canal and the covering of the spinal cord or giving it into a vein may help lessen pain caused by cancer surgery.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00295945
- Testing
- fentanyl citrate, hydromorphone hydrochloride, ropivacaine hydrochloride
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- University of California, San Francisco
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Metastatic Ewing Sarcoma, Metastatic Osteosarcoma
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
This phase II trial studies how well cabozantinib s-malate works in treating patients with osteosarcoma or Ewing sarcoma that has grown or returned (come back) after a period of improvement.
- Conditions
- Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma
- Trial name
- NCT02243605
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Where
- 11 sites in France
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)